John T. Schousboe, MD, MS; John A. Nyman, PhD; Robert L. Kane, MD; Kristine E. Ensrud, MD, MPH
Potential Financial Conflicts of Interest: Grants received: J.T. Schousboe (Hologic, Inc.), K.E. Ensrud (Eli Lilly & Co., Pfizer, NPB Pharmaceuticals).
Requests for Single Reprints: John T. Schousboe, MD, MS, Park Nicollet Clinic, 3800 Park Nicollet Boulevard, Minneapolis, MN 55416; e-mail, email@example.com.
Current Author Addresses: Dr. Schousboe: Park Nicollet Clinic, 3800 Park Nicollet Boulevard, Minneapolis, MN 55416.
Drs. Nyman and Kane: Division of Health Services Research and Policy, School of Public Health, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455.
Dr. Ensrud: Department of Medicine, Minneapolis Veterans Administration Medical Center, 1 Veterans Drive, Minneapolis, MN 55417.
Author Contributions: Conception and design: J.T. Schousboe, R.L. Kane.
Analysis and interpretation of the data: J.T. Schousboe, J.A. Nyman, K.E. Ensrud.
Drafting of the article: J.T. Schousboe.
Critical revision of the article for important intellectual content: J.T. Schousboe, R.L. Kane, K.E. Ensrud.
Final approval of the article: J.T. Schousboe, R.L. Kane, K.E. Ensrud.
Administrative, technical, or logistic support: J.T. Schousboe, R.L. Kane.
Collection and assembly of data: J.T. Schousboe.
Treatment guidelines recommend drug treatment to prevent fractures for some postmenopausal women who have low bone mass (osteopenia) but do not have osteoporosis or a history of clinical fractures.
To estimate the societal costs and health benefits of alendronate drug treatment to prevent fractures in postmenopausal women with osteopenia.
Markov model with 8 health states: no fracture, post-distal forearm fracture, post-clinical vertebral fracture, post-radiographic (but clinically inapparent) vertebral fracture, post-hip fracture, post-hip and vertebral fractures, post-other fracture, and death.
Population-based studies of age-specific fracture rates and costs, prospectively measured estimates of disutility after fractures, and the Fracture Intervention Trial of alendronate versus placebo to prevent fracture.
Postmenopausal women 55 to 75 years of age with femoral neck T-scores between −1.5 and −2.4.
Five years of alendronate therapy or no drug treatment.
Costs, quality-adjusted life-years, and incremental cost-effectiveness ratios.
For women with no additional fracture risk factors, the cost per quality-adjusted life-year gained ranged from $70 000 to $332 000, depending on age and femoral neck bone density.
Results were sensitive to changes in fracture risk reduction attributable to alendronate and alendronate cost.
Results apply only to postmenopausal white women residing in the United States.
Alendronate therapy for postmenopausal women with femoral neck T-scores better than −2.5 and no history of clinical fractures or other bone mineral density-independent risk factors for fracture is not cost-effective, assuming U.S. costs of alendronate and currently available estimates of alendronate efficacy in osteopenic women.
Schousboe JT, Nyman JA, Kane RL, Ensrud KE. Cost-Effectiveness of Alendronate Therapy for Osteopenic Postmenopausal Women. Ann Intern Med. ;142:734–741. doi: 10.7326/0003-4819-142-9-200505030-00008
Download citation file:
Published: Ann Intern Med. 2005;142(9):734-741.
Emergency Medicine, Endocrine and Metabolism, Healthcare Delivery and Policy, Metabolic Bone Disorders.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use